Gyre Therapeutics, Inc.
GYRE
$8.68
-$2.53-22.57%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -20.86% | 9.35% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -20.86% | 9.35% | |||
| Cost of Revenue | -24.04% | 22.86% | |||
| Gross Profit | -20.72% | 8.83% | |||
| SG&A Expenses | -29.23% | 27.38% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -27.29% | 28.01% | |||
| Operating Income | 242.84% | -84.34% | |||
| Income Before Tax | 500.39% | -80.36% | |||
| Income Tax Expenses | 343.84% | -81.10% | |||
| Earnings from Continuing Operations | 556.24% | -80.08% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -55.09% | 61.43% | |||
| Net Income | 2,825.25% | -108.81% | |||
| EBIT | 242.84% | -84.34% | |||
| EBITDA | 147.62% | -75.81% | |||
| EPS Basic | 2,700.00% | -109.16% | |||
| Normalized Basic EPS | 841.38% | -134.12% | |||
| EPS Diluted | 226.47% | -125.95% | |||
| Normalized Diluted EPS | 727.59% | -140.85% | |||
| Average Basic Shares Outstanding | 0.54% | 0.36% | |||
| Average Diluted Shares Outstanding | 18.64% | -16.26% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||